INTRODUCTION
Increasing evidence suggests genetic and epigenetic events, and environmental factor contribute to the development of melanoma [1] [2] [3] . DNA methylation, a frequent epigenetic modification, is closely associated with the tumorigenesis, progression and prognosis of many types of human cancer 4, 5 . Mapped to human chromosome 10q26, O 6 -methylguanine-DNA methyltransferase (MGMT) belongs to a DNA repair gene and counteracts the chemotherapeutic effects of alkylating agent, which protects tumor cells 6, 7 . MGMT gene within the promoter region is frequently methylated in various cancers, including primary or metastatic melanoma 5, 8, 9 . However, there are some conflicting and different data about MGMT promoter methylation in patients with melanoma. For example, Marini et al. 10 reported that MGMT promoter methylation had a different frequency in primary and metastatic melanoma (64% vs. 15%). Hoon et al. 11 reported that 
RESULTS

Study characteristics
Through the detailed steps of the systematic literature search, according to the above selection standards ( Fig. 1 95% CI=2.90∼16.90, p＜0.001 and blood: OR=12.04, 95% CI=2.15∼67.42, p=0.005) (Fig. 3) .
Subgroup analysis by detection method demonstrated that
MGMT promoter methylation was associated with metastatic melanoma in the MSP method (OR=8.85, 95% CI=3.83∼20.49, p＜0.001), but not in the QMSP method (OR=3.37, 95% CI=0.37∼30.64, p=0.281) (Fig. 4) DISCUSSION DNA methylation of tumor suppressor genes (TSGs) within the promoter region is a major molecular mechanism of epigenomic regulation, which results in the dysfunction or loss of the related gene expression and may play a key role in cancer development 23, 24 . MGMT has been identified as a key TSG 25 , loss of MGMT expression through promoter methylation has been reported in melanoma 11, 15 .
However, the clinical effect of MGMT promoter methylation remains unclear in melanoma. We performed this meta-analysis to estimate whether MGMT promoter methylation provided valuable insight as an epigenetic biomarker for patients with melanoma. Our meta-analysis included all eligible articles, which were performed in Caucasian population. The results
shown that MGMT promoter methylation was notably higher in primary or metastatic melanoma than in normal controls, which suggested that MGMT promoter methylation may be correlated with the development of melanoma. Additionally, when metastatic melanoma was compared to primary melanoma, MGMT promoter methylation was not found to be statistically significantly higher in metastatic melanoma than in primary melanoma (p=0.432 MGMT promoter methylation using multivariate analysis.
Third, the sample sizes of subgroup analyses were smaller, more studies with large population are essential in the future, especially in blood samples. Finally, in order to compare "future" Asian data, additional studies with the detailed clinical subtype of melanoma (such as acral lentiginous melanoma, superficial spreading melanomas, nodular melanomas, etc.) are needed.
In conclusion, the current findings indicate that MGMT promoter methylation in primary or metastatic melanoma has a higher level than in normal controls. MGMT promoter methylation had a similar frequency in metastatic and primary melanoma, and it may not be correlated with response to drug therapy and the prognosis in OS and PFS. MGMT promoter methylation may be a potential biomarker using blood samples for metastatic melanoma. More prospective studies using large sample sizes are essential to further validate our findings in the future.
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